Clinical trial · Observational
Genetic Alteration After Systemic Treatment in Breast Cancer
NCT02591966CI-TRIAL-00031245unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate effects of systemic treatments on genomic profiles in patients with breast cancer and to compare genomic profiling between premenopausal and postmenopausal women by systemic treatments in breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Biomarker group
- description
- 1. The patients who receive neoadjuvant systemic treatments: 2. The patients who have distant metastatic sites at first and recur from surgery: 3. The patients who are going to receive first-line chemotherapy:
Primary outcomes (1)
- measure
- Genomic profiling will be assessed by tissue sampling and blood.
- timeFrame
- 2year
- description
- Tissue and blood will be tested for CancerSCAN, cfDNA, WES, WTS, FACS, cytokine and immunologic signature analysis platform.NAC to study the multiscale relationships among DCE-MRI features, NGS data, and pathologic response to NAC and to evaluate the role of radiogenomics in predicting pathologic response of the patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients older than 20 years 2. Patients with histologically confirmed breast cancer at three disease status * Patients who are going to receive neoadjuvant chemotherapy with feasible biopsy site. * Patients who recur from curative surgery and have distant metastasis with feasible biopsy site. ; Patients must have received adjuvant chemotherapy after curative surgery. * Patients who are going to first-line palliative chemotherapy with feasible biopsy site. 3. Patients with PS ECOG 0 - 2 4. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. 5. Written informed consent form 6. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to study as defined below: * Haemoglobin ≥9.0 g/L (transfusion allowed) * White blood cells (WBC) \> 3 x 109/L * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) * AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN Exclusion Criteria: 1. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical condition that would interfere with the subject's safety. 2. Double primary cancer (except for any cancer in remission for \> 5 years, cervix cancer in situ, basal cell cancer in situ, any in situ cancers that are resected)
References
Publications (0)
Data not yet available
No reference posted for this study.